scholarly journals Identifying the Components of Acidosis in Patients With Severe Plasmodium falciparum Malaria Using Metabolomics

2018 ◽  
Vol 219 (11) ◽  
pp. 1766-1776 ◽  
Author(s):  
Stije J Leopold ◽  
Aniruddha Ghose ◽  
Erik L Allman ◽  
Hugh W F Kingston ◽  
Amir Hossain ◽  
...  

AbstractBackgroundAcidosis in severe Plasmodium falciparum malaria is associated with high mortality, yet the pathogenesis remains incompletely understood. The aim of this study was to determine the nature and source of metabolic acids contributing to acidosis in patients with severe falciparum malaria.MethodsA prospective observational study was conducted to characterize circulating acids in adults with P. falciparum malaria (n = 107) and healthy controls (n = 45) from Bangladesh using high-resolution liquid chromatography–mass spectrometry metabolomics. Additional in vitro P. falciparum culture studies were performed to determine if parasites release the acids detected in plasma from patients with severe malaria acidosis.ResultsWe identified previously unmeasured plasma acids strongly associated with acidosis in severe malaria. Metabolomic analysis of P. falciparum parasites in vitro showed no evidence that these acids are released by the parasite during its life cycle. Instead, 10 of the plasma acids could be mapped to a gut microbial origin. Patients with malaria had low L-citrulline levels, a plasma marker indicating reduced gut barrier integrity. Longitudinal data showed the clearance of these newly identified acids was delayed in fatal cases.ConclusionsThese data suggest that a compromise in intestinal barrier function may contribute significantly to the pathogenesis of life-threatening acidosis in severe falciparum malaria.Clinical Trials RegistrationNCT02451904.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 666-666
Author(s):  
Christine Cserti-Gazdewich ◽  
Charles Musoke ◽  
Aggrey Dhabangi ◽  
Deborah Nakiboneka-Ssenabulya ◽  
Henry Ddungu ◽  
...  

Abstract Abstract 666 Background: Plasmodium falciparum malaria has been called the greatest force in human evolution as a result of its disproportionate lethality among children and its longstanding presence in human history. Malaria's complex pathogenesis is based in part on cytoadhesion, which is mediated by a parasite-derived surface protein (PfEMP1) expressed on infected erythrocytes. PfEMP1 binds with ligands on red cells, platelets, and endothelium, and through the lectin-like DBL1α domain, binds preferentially to blood Group A. This contributes to the obstruction of microvascular perfusion and to cerebral malaria, lactic acidosis, and death. Initial studies demonstrated increased cytoadhesion to Group A RBC in vitro, suggesting that Group A hosts may be at risk of greater morbidity with P falciparum. Subsequently, retrospective clinical studies demonstrated a higher proportion of Group A individuals among those with severe disease. Recently, attention has focused on malaria pathogenesis and von Willebrand factor, which is elevated in Group A individuals. While the cumulative evidence suggests a central role for ABO in malaria, proof for a driving effect on the evolutionary distribution of ABO blood groups has awaited definitive study of the relationship between ABO and P falciparum malaria mortality. We report here initial findings from the Cytoadherence in Pediatric Malaria (CPM) Study (clinicaltrials.gov, NCT 00707200) which was designed to examine associations between malaria outcomes and host blood groups implicated in erythrocyte cytoadhesion. Methods: We performed a 2 year prospective observational study of children with acute malaria (age 6 mo – 12 yr) presenting for care at Mulago Hospital, Uganda. HIV positive patients were excluded from analysis. We enrolled children who met pre-study WHO criteria for either Uncomplicated Malaria (UM) or Severe Malaria (SM). Patients were followed from the time of presentation to discharge or death. ABO blood groups were determined by standard hemagglutination. The study was approved by the Uganda National Council on Science and Technology and all participating institutions. Results: At the study's conclusion (October 2009), 2092 children were enrolled. Children with HIV (n=45), those whose blood smears lacked species-confirmed P falciparum parasitemia on review by an external, blinded reference parasitology laboratory (n=35), and one child outside of the pre-defined study age range were excluded, leaving 2011 for analysis. Of these, 1078 had UM and 855 had SM, with 48 of the SM (5.6%) being fatal cases. Among those with SM, 850 had either cerebral malaria (CM, n=174), severe malaria anemia (SMA, hemoglobin < 5g/dL, n=558), or lactic acidosis (LA, lactate >5mM, n=482) in an overlapping distribution. The proportion of individuals with Group A or AB increased with categories of increasing disease severity (UM = 28%, SM = 37.1%; fatal = 47.9%). Group O correspondingly decreased (UM = 49.9%, SM = 40.6%, fatal = 37.5%). There was a highly statistically significant difference in the distribution of A, B, AB and O between UM and SM, χ2 =29.57, p=0.000002. Importantly, we observed a significant difference between UM and fatal cases for the distribution of all four ABO groups (χ2 = 4.624, p=0.0315) which was especially significant for Group A or AB versus O (χ2 = 5.946, p=0.0147). A significant difference in ABO distribution was also observed for specific severe malaria syndromes, with Group O enriched for UM and Group A or AB enriched among those with CM (χ2= 12.18, p=0.006791) and SMA (χ2 = 34.24, p<10−5). Conclusions: This is the largest prospective study on the relationship between ABO blood groups and P falciparum malaria and the first report sufficiently powered to demonstrate the effect of ABO on survival in P falciparum malaria. We report a statistically significant and clinically important advantage among group O hosts and a corresponding disadvantage for group A or AB hosts. Our results confirm clinically the findings of in vitro studies on ABO and cytoadhesion as well as prior retrospective studies on ABO and disease severity. Because our study was conducted in children, the results have direct bearing on the effect of malaria on genetic selection. The results have implications for the pathogenesis of P falciparum malaria, for new treatment strategies aimed at interrupting cytoadhesion, and for our understanding of the worldwide distribution of ABO blood groups. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Minh Cuong Duong ◽  
Oanh Kieu Nguyet Pham ◽  
Phong Thanh Nguyen ◽  
Van Vinh Chau Nguyen ◽  
Phu Hoan Nguyen

Abstract Background Drug-resistant falciparum malaria is an increasing public health burden. This study examined the magnitude of Plasmodium falciparum infection and the patterns and predictors of treatment failure in Vietnam. Methods Medical records of all 443 patients with malaria infection admitted to the Hospital for Tropical Diseases between January 2015 and December 2018 were used to extract information on demographics, risk factors, symptoms, laboratory tests, treatment, and outcome. Results More than half (59.8%, 265/443, CI 55.1–64.4%) of patients acquired Plasmodium falciparum infection of whom 21.9% (58/265, CI 17.1–27.4%) had severe malaria, while 7.2% (19/265, CI 4.6–10.9%) and 19.2% (51/265, CI 14.7–24.5%) developed early treatment failure (ETF) and late treatment failure (LTF) respectively. Among 58 patients with severe malaria, 14 (24.1%) acquired infection in regions where artemisinin resistance has been documented including Binh Phuoc (11 patients), Dak Nong (2 patients) and Gia Lai (1 patient). Under treatment with intravenous artesunate, the median (IQR) parasite half-life of 11 patients coming from Binh Phuoc was 3 h (2.3 to 8.3 h), two patients coming from Dak Nong was 2.8 and 5.7 h, and a patient coming from Gia Lai was 6.5 h. Most patients (98.5%, 261/265) recovered completely. Four patients with severe malaria died. Severe malaria was statistically associated with receiving treatment at previous hospitals (P < 0.001), hepatomegaly (P < 0.001) and number of inpatient days (P < 0.001). Having severe malaria was a predictor of ETF (AOR 6.96, CI 2.55–19.02, P < 0.001). No predictor of LTF was identified. Conclusions Plasmodium falciparum remains the prevalent malaria parasite. Despite low mortality rate, severe malaria is not rare and is a significant predictor of ETF. To reduce the risk for ETF, studies are needed to examine the effectiveness of combination therapy including parenteral artesunate and a parenteral partner drug for severe malaria. The study alerts the possibility of drug-resistant malaria in Africa and other areas in Vietnam, which are known as non-endemic areas of anti-malarial drug resistance. A more comprehensive study using molecular technique in these regions is required to completely understand the magnitude of drug-resistant malaria and to design appropriate control strategies.


Author(s):  
Mélissa Mairet-Khedim ◽  
Sandrine Nsango ◽  
Christelle Ngou ◽  
Sandie Menard ◽  
Camille Roesch ◽  
...  

Abstract Background Dihydroartemisinin/piperaquine is increasingly used for the treatment of uncomplicated Plasmodium falciparum malaria in Africa. The efficacy of this combination in Cameroon is poorly documented, while resistance to dihydroartemisinin/piperaquine readily spreads in Southeast Asia. Objectives This study evaluated the clinical efficacy of dihydroartemisinin/piperaquine in Cameroon, as well as the molecular profile and phenotypic susceptibility of collected isolates to dihydroartemisinin and piperaquine. Patients and methods Dihydroartemisinin/piperaquine efficacy in 42 days was followed-up for 138 patients presenting non-complicated falciparum malaria. Piperaquine concentration was determined at day 7 for 124 patients. kelch13 gene polymorphisms (n = 150) and plasmepsin2 gene amplification (n = 148) were determined as molecular markers of resistance to dihydroartemisinin and piperaquine, respectively. Parasite susceptibility to dihydroartemisinin and piperaquine was determined using validated in vitro survival assays. Results The efficacy of dihydroartemisinin/piperaquine treatment was 100% after PCR correction. The reinfections were not associated with a variation of piperaquine concentration at day 7. Ninety-six percent (144/150) of the samples presented a WT allele of the kelch13 gene. Two percent (3/150) presented the non-synonymous mutation A578S, which is not associated with resistance to dihydroartemisinin. No duplication of the plasmepsin2 gene was observed (0/148). All the samples tested in vitro by survival assays (n = 87) were susceptible to dihydroartemisinin and piperaquine. Conclusions Dihydroartemisinin/piperaquine has demonstrated excellent therapeutic efficacy with no evidence of emerging artemisinin or piperaquine resistance in Yaoundé, Cameroon. This observation suggests that dihydroartemisinin/piperaquine could be a sustainable therapeutic solution for P. falciparum malaria if implemented in areas previously free of artemisinin- and piperaquine-resistant parasites, unlike Southeast Asia.


2004 ◽  
Vol 71 (3) ◽  
pp. 294-296 ◽  
Author(s):  
AGNÉS AUBOUY ◽  
ANNICK KEUNDJIAN ◽  
MOHAMED BAKARY ◽  
PHILIPPE DELORON ◽  
JACQUES LE BRAS ◽  
...  

2013 ◽  
Vol 13 (12) ◽  
pp. 1043-1049 ◽  
Author(s):  
Benoit Witkowski ◽  
Chanaki Amaratunga ◽  
Nimol Khim ◽  
Sokunthea Sreng ◽  
Pheaktra Chim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document